(Q40891944)

24 September 2017

title

Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor (English)

1 reference

24 September 2017

0 references

1 reference

Fischel JL

1

1 reference

24 September 2017

Formento P

2

1 reference

24 September 2017

Etienne MC

3

1 reference

24 September 2017

Spector T

4

1 reference

24 September 2017

Renée N

5

1 reference

24 September 2017

Milano G

6

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 June 1997

1 reference

24 September 2017

published in

Biochemical Pharmacology

1 reference

24 September 2017

volume

53

1 reference

24 September 2017

issue

11

1 reference

24 September 2017

page(s)

1703-1709

1 reference

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

Pharmacokinetics of Leucovorin Metabolites in Human Plasma as a Function of Dose Administrated Orally and Intravenously

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2982455-0

10.1016/S0006-2952(97)82455-0

7 January 2021

Identifiers

DOI

1 reference

24 September 2017

1 reference